Uveal melanomaFrancesco Spagnolo(National Cancer Research Institute), Graziano Caltabiano, Paola QueiroloCancer Treatment ReviewsJanuary 29, 201210.1016/j.ctrv.2012.01.002Cited by 166SaveCiteExport RISWatch citationsAbstractRelated PapersThe COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality FindingsMarie Diener‐West, John D. Earle, Shai Fine et al.|Archives of Ophthalmology|2001|772Prognostic implications of monosomy 3 in uveal melanomaN Bornfeld, Gabriele Prescher, R Becher et al.|The Lancet|1996|762Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal MelanomaMarie Diener‐West, Sandra M. Reynolds, Donna J Agugliaro et al.|Archives of Ophthalmology|2005|617Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RASWieke Zuidervaart, Frans van Nieuwpoort, Mitchell Stark et al.|British Journal of Cancer|2005|217Prognosis of Uveal Melanoma in 500 Cases Using Genetic Testing of Fine-Needle Aspiration Biopsy SpecimensCarol L. Shields, Arupa Ganguly, Carlos Bianciotto et al.|Ophthalmology|2010|200